Angle says key biopsy product successfully used in melanoma analysis

Writer, Stock Market Wire
Tuesday, January 29, 2019 - 13:37

Liquid biopsy company Angle said a key product had been been successfully used to improve the workflows and sensitivity of lymph node analysis in melanoma.

The related research, led by Dr Bernhard Polzer at the Fraunhofer Institute for Toxicology and Experimental Medicine, was published in the International Journal of Cancer.

'This is another example of our leveraged approach with research customers delivering new applications for Parsortix,' chief executive Andrew Newland said.

'There is now the potential for the Parsortix system to be adopted as a standard approach for analysing lymph nodes, which is a requirement for all patients diagnosed with melanoma and several other cancer types.'

At 1:37pm: (LON:AGL) Angle PLC share price was +2.5p at 57.5p


Related content

Angle intellectual property strengthens after Queen Mary University of London granted patent

Angle said its ability to offer megakaryocyte tests to its existing circulating tumor cells tests received a boost after the Queen Mary University of London...

Fri, 04/10/2019 - 08:59


University of Birmingham finds Angle's Liquid biopsy system holds key advantages over rivals to treat head and neck cancer

Liquid biopsy company Angle said the University of Birmingham had published research indicating the potential of using CTC liquid biopsies to improve treatment of head...

Fri, 13/09/2019 - 09:55


Angle to raise £18m to invest in products, cut debt

Liquid biopsy company Angle launched a share issue to raise £18.0m to develop its products, establish a service laboratroy and strengthen its balance sheet.

News...

Tue, 25/06/2019 - 13:22


Angle says study demonstrates effective use of its biopsy technology

Liquid biopsy company Angle said the University Medical Centre Hamburg-Eppendorf had published results of work demonstrating that its technology could be used to investigate the...

Fri, 21/06/2019 - 14:51


Angle reports 'positive' pre-study ovarian cancer clinical results

Angle reported 'positive' results from the first phase of its ovarian cancer clinical verification study.

The pre-study results demonstrated that the optimisation of the...

Wed, 05/06/2019 - 10:29